Sangamo Therapeutics plunges after Pfizer terminates partnership

Sangamo Therapeutics

30/12/2024 21:39

** Drug developer Sangamo Therapeutics' shares  SGMO.O  fall 47.4% to $1.23 in extended
trading
    ** SGMO said that Pfizer  PFE.N  terminated partnership to develop hemophilia A gene therapy
    ** Co's collaboration and license agreement with Pfizer will terminate, effective April 21,
2025
    ** In July, PFE announced positive results from a late-stage study of therapy
    ** SGMO said it plans to explore all options to commercialize the hemophilia A gene therapy,
including seeking a new partner
    ** Up to Monday's close, SGMO is up 330.7% YTD

 (Reporting by Rishi Kant in Bengaluru)
 ((Rishi.Kant@thomsonreuters.com))